Oncogenic Role of Engrailed (EN)-2 in Epithelial Ovarian Neoplasms

Sponsor

Sohag University (Other)

Overall Status

Completed

CT.gov ID

NCT05553067

Collaborator

(none)

100

Enrollment

Location

Actual Duration (Months)

1.1

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Detection of the potential oncogenic role of Engrailed-2 in epithelial ovarian neoplasms, in order to detect biological markers that could be targeted and blocked by new medications.

Condition or Disease	Intervention/Treatment	Phase
Ovarian Neoplasms	Genetic: Immunohistochemical staining of normal and neoplastic ovarian tissues by anti human Engrailed-2 antibody.

Detailed Description

Epithelial ovarian carcinomas represent more than 90% of all ovarian carcinomas. Treatment of these ovarian carcinomas on basis of their histopathological features didn't improve patients' outcomes with very high incidence of relapses and resistance to therapy. Detection of novel biological markers which are involved in tumor progression could have promising results if these biological molecules are targeted and blocked by new medications.

Engrailed-2 is a protein encoded by a gene located on chromosome 7. Engrailed-2 is involved in neural development and neural connections during embryological life. it has been proved that Engrailed-2 is expressed in non neural neoplasms, especially in prostatic and urinary bladder carcinomas. Now estimatiion of urinary and serum levels of Engrailed-2 is used as a non-invasive screening tool in to detect prostatic and urinary bladder carcinomas. We aim to evaluated immunohistochemical expression of Engrailed-2 in normal and neoplastic ovarian tissues and to compare such expression between normal and neoplastic tissues in order to improve its oncogenic role in ovarian carcinoma.

Study Design

Study Type:

Observational

Actual Enrollment :

100 participants

Observational Model:

Case-Only

Time Perspective:

Retrospective

Official Title:

Oncogenic Role of Engrailed (EN)-2 in Epithelial Ovarian Neoplasms.

Actual Study Start Date :

Jan 1, 2015

Actual Primary Completion Date :

Dec 31, 2021

Actual Study Completion Date :

Jun 1, 2022

Outcome Measures

Primary Outcome Measures

compare levels of Engrailed-2 expression in different ovarian specimens. [December, 2021]
compare levels of immunohistochemical expression of Engrailed-2 in normal and neoplastic ovarian tissues. and correlate Engrailed-2 expression in neoplastic ovarian tissues to patients' ages, tumor phenotype and state of nodal metastasis.

Eligibility Criteria

Criteria

Ages Eligible for Study:

20 Years to 70 Years

Sexes Eligible for Study:

Female

Inclusion Criteria:

All types of epithelial ovarian neoplasms (benign, borderline and malignant).

Exclusion Criteria:

Non-epithelial and/ or secondary ovarian tumors.
Cases with poor clinical data.
Cases who had history of pre-operative chemotherapy.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Sohag faculty of medicine	Sohag		Egypt	82524

Sponsors and Collaborators

Sohag University

Investigators

Principal Investigator: Maisa H Mohammed, MD, Sohag University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

Responsible Party:

Maisa Hashem Mohammed, Lecturer of Pathology, Sohag University

ClinicalTrials.gov Identifier:

NCT05553067

Other Study ID Numbers:

Soh-Med-22-09-13

First Posted:

Sep 23, 2022

Last Update Posted:

Sep 27, 2022

Last Verified:

Sep 1, 2022

Individual Participant Data (IPD) Sharing Statement:

Yes

Plan to Share IPD:

Yes

Studies a U.S. FDA-regulated Drug Product:

Studies a U.S. FDA-regulated Device Product:

Additional relevant MeSH terms:

Neoplasms

Ovarian Neoplasms

Antibodies

Study Results

No Results Posted as of Sep 27, 2022